BioWorld - Monday, March 30, 2020

Neurology/Psychiatric, BioWorld MedTech
%{topic} RSS Feed RSS

3-27-Pear-Somryst.png

FDA authorizes Pear Therapeutics' prescription digital insomnia therapy

March 27, 2020
By Annette Boyle
No Comments
Pear Therapeutics Inc. obtained FDA approval for Somryst, the first prescription digital therapeutic for chronic insomnia. The app provides structured cognitive behavior therapy (CBT) with clinical dashboards for physicians. While CBT is the recommended first-line therapy for insomnia, the U.S. has only 500 therapists certified to provide CBT for insomnia (CBTi) for the estimated 30 million Americans who suffer from chronic difficulty going to and staying asleep.
Read More
3-19-Sandia-MEG.png

Sandia Labs develops a wearable brain imager

March 19, 2020
By Annette Boyle
No Comments
Albuquerque, N.M.-based Sandia Labs received a $16 million grant from the NIH to build a prototype for a wearable brain scanner. The noninvasive functional brain imaging system will use optically pumped magnetometers (OPMs) to conduct more accurate magnetoencephalography (MEG), while improving accuracy, increasing comfort, reducing imaging costs, and enabling use in more patients.
Read More
neurology-brain-protect.png

Keystone Heart secures CE mark for Triguard 3

March 10, 2020
By Liz Hollis
No Comments
Keystone Heart Ltd., of Caesarea, Israel and Tampa, Fla., scored a win in Europe after obtaining the CE mark for the Triguard 3 cerebral embolic protection (CEP) device. It is designed to minimize the risk of cerebral damage by deflecting embolic debris away from cerebral circulation during transcatheter aortic valve implantation (TAVI) and other transcatheter heart procedures. According to the company, the device is the only product with a CE mark designed to cover and protect all three major cerebral aortic arch vessels.
Read More
3-9-Insightec-MRI.png

Insightec aims for $150M in series F round

March 9, 2020
By Meg Bryant
No Comments
Tirat Carmel, Israel-based Insightec Ltd. has inked a deal for a series F financing of up to $150 million led by Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries. The round, which has a post-money valuation of $1.3 billion, is earmarked for continued study of the company’s low-intensity, focused ultrasound technology in treating certain movement disorders.
Read More

Popular Stories

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe